Alemtuzumab in refractory Sézary syndrome

Sézary syndrome is a primary cutaneous t-cell lymphoma characterized by the triad of erythroderma,lymphadenopathy and circulating atypical cells. the emergence of new molecular targets has enabled the development of drugs such as alemtuzumab,an anti-cd52 monoclonal antibody,which has shown promising results in the treatment of this entity. we report the case of a 70-year-old male with refractory sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. the treatment was discontinued after 4 months due to adverse effects,with the patient showing a sustained response without disease progression after 13 months of follow-up. © 2016 by anais brasileiros de dermatologia.